Speaker
Description
Among the new materials exhibiting theranostic potential are undoubtedly magnetic iron oxide nanoparticles (IONPs) [1]. Due to their size, they can interact at the cellular and molecular level of biological systems. In turn, their unique magnetic properties mean that they can be used as contrast agents in MRI and as carriers for targeted drug transport, allowing for simultaneous monitoring of pharmaceutical distribution. IONPs can also induce local hyperthermia in response to an external magnetic field and thus selectively destroy cancer cells [2-5].
Extensive efforts are now underway to design IONPs with the desired physicochemical properties. However, in order to translate these theranostic nanomaterials (NMs) into clinical practice, the research aiming at determination of the biocompatibility of IONPs and the safety of their use in humans are necessary. The toxicity studies of NMs are mainly carried out in vitro on cell lines and cultures. In vitro experiments provide mechanistic information on the toxicity of NMs and, in particular, on their genotoxicity, cytotoxicity, the possibility of causing oxidative stress or the development of inflammatory processes in cells. They are, therefore, a very important step in the complex process of enhancing NMs biocompatibility and their biomedical potential [6]. However, their results cannot be directly translated into in vivo models, which are still crucial and mandatory before the first human studies [7-8].
The talk will present the results of own research demonstrating how the use of instrumental techniques, including the methods of atomic and molecular spectroscopy, can support the characterization of the properties of IONPs and the assessment of their toxicity and therapeutic potential in vitro and in vivo [9-12].
References:
[1] Zhu L, Zhou Z, Mao H, Yang L (2017) Nanomedicine (Lond) 12:73-87. [2] Corot C, Robert P, Idée JM, Port M (2006) Adv Drug Deliv Rev 58:1471-1504. [3] Pankhurst QA, Connolly J, Jones SK, Dobson J (2003) J Phys D Appl Phys 36:167-181. [4] Dobson J (2006) Drug Dev Res 67:55-60. [5] Sun C, Lee JS, Zhang M (2008) Adv Drug Deliv Rev 60:1252-1265. [6] Dhawan A and Sharma V (2010) Anal Bioanal Chem 398:589-605. [7] Steger-Hartmann T and Raschke M (2020) Curr Opin Toxicol 23-24: 6-10. [8] Nayak R, Meerovich I, Dash AK (2019) AAPS PharmSciTech 20:160. [9] Matusiak K, Skoczen A, Setkowicz Z, Kubala-Kukus A, Stabrawa I, Ciarach M, Janeczko K, Jung A, Chwiej J (2017) Nanotoxicology 11:1225-1236. [10] Skoczen A, Matusiak K, Setkowicz Z, Kubala-Kukus A, Stabrawa I, Ciarach M, Janeczko K, Chwiej J (2018) Chem Res Toxicol 31:876-884. [11] Janik-Olchawa N, Drozdz A, Ryszawy D, Pudełek M, Planeta K, Setkowicz Z, Sniegocki M, Zadło A, Ostachowicz B, Chwiej J (2020) Sci Rep 10:15447. [12] Drozdz A, Matusiak K, Setkowicz Z, Ciarach M, Janeczko K, Sandt C, Borondics F, Horak D, Babic M, Chwiej J (2020) Spectrochim Acta A Mol Biomol Spectrosc 236:118355.
